Summit Therapeutics Inc. held $225.3M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 9 fiscal years, from 2018 to 2025, and the quarters Summit Therapeutics Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
SMMT Debt & Cash by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
SMMT Debt & Cash by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K | Q3'2410-Q | Q2'24Filing | Q1'24Filing | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $100.0M | $100.0M-79.8% |
| Cash & Equivalents | $150.8M-36.8% | $419.4M+40.8% | $106.5M-49.6% | $225.3M+114.8% | $238.6M+154.4% | $297.9M+947.6% | $211.5M+245.1% | $104.9M+46.8% | $93.8M+294.1% | $28.4M-32.5% | $61.3M-13.6% | $71.4M-79.5% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Summit Therapeutics Inc. financials
Frequently Asked Questions
Summit Therapeutics Inc. held $225.3M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Summit Therapeutics Inc. (SMMT) reported on that line in every period on record.